DNLI · Categories · Form 4

DNLI - SEC Form 4 insider transactions

Denali Therapeutics Inc. (DNLI) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for DNLI

• 4d
  Director Flatley Jay T was granted 6,408 shares, increasing direct ownership by 40% to 22,628 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 4d
  Director Klein Peter S was granted 6,408 shares, increasing direct ownership by 23% to 33,941 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 4d
  Director Krognes Steve E. was granted 6,408 shares, increasing direct ownership by 20% to 38,202 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 4d
  Director Schenkein David P was granted 6,408 shares, increasing direct ownership by 42% to 21,665 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 4d
  Director Thornberry Nancy was granted 6,408 shares, increasing direct ownership by 26% to 31,125 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 4d
  Director Van Hauwermeiren Timothy was granted 6,408 shares, increasing direct ownership by 60% to 17,040 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 4d
  Director Cook Jennifer E. was granted 6,408 shares, increasing direct ownership by 25% to 32,483 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 4d
  Director Baker Bros. Advisors Lp was granted 12,816 shares (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 152d
  President and CEO Watts Ryan J. sold $580,767 worth of shares (35,198 units at $16.50), decreasing direct ownership by 11% to 296,833 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 152d
  COFO and Secretary Schuth Alexander O. sold $284,097 worth of shares (17,218 units at $16.50), decreasing direct ownership by 6% to 282,828 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 154d
  COFO and Secretary Schuth Alexander O. was granted 57,700 shares, increasing direct ownership by 24% to 300,046 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 154d
  President and CEO Watts Ryan J. was granted 78,960 shares, increasing direct ownership by 31% to 332,031 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 176d
  SEC Form 4 filed by Director Baker Bros. Advisors Lp

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 214d
  Director Van Hauwermeiren Timothy was granted 10,632 shares (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 277d
  President and CEO Watts Ryan J. gifted 50,000 shares (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 298d
  COFO and Secretary Schuth Alexander O. sold $39,884 worth of shares (2,937 units at $13.58), decreasing direct ownership by 1% to 242,346 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 298d
  Chief Medical Officer Ho Carole sold $51,684 worth of shares (3,743 units at $13.81), decreasing direct ownership by 2% to 216,585 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 306d
  Chief Medical Officer Ho Carole exercised 44,655 shares at a strike of $0.68, increasing direct ownership by 25% to 220,328 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 333d
  President and CEO Watts Ryan J. exercised 495,282 shares at a strike of $1.05 and sold $7,429,230 worth of shares (495,282 units at $15.00) (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 369d
  Director Baker Bros. Advisors Lp was granted 21,130 shares (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 369d
  Director Cook Jennifer E. was granted 6,037 shares, increasing direct ownership by 30% to 26,075 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 369d
  Director Flatley Jay T was granted 6,037 shares, increasing direct ownership by 59% to 16,220 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 369d
  Director Klein Peter S was granted 6,037 shares, increasing direct ownership by 28% to 27,533 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 369d
  Director Krognes Steve E. was granted 6,037 shares, increasing direct ownership by 23% to 31,794 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 369d
  Director Schenkein David P was granted 6,037 shares, increasing direct ownership by 65% to 15,257 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 369d
  Director Thornberry Nancy was granted 6,037 shares, increasing direct ownership by 32% to 24,717 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 369d
  Director Tessier-Lavigne Marc was granted 6,037 shares, increasing direct ownership by 0.32% to 1,886,576 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 516d
  Chief Medical Officer Ho Carole sold $308,291 worth of shares (15,162 units at $20.33), decreasing direct ownership by 8% to 175,673 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 516d
  COFO and Secretary Schuth Alexander O. sold $308,291 worth of shares (15,162 units at $20.33), decreasing direct ownership by 6% to 244,308 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 516d
  President and CEO Watts Ryan J. sold $750,955 worth of shares (36,916 units at $20.34), decreasing direct ownership by 13% to 253,071 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 516d
  Director Krognes Steve E. sold $69,485 worth of shares (3,339 units at $20.81), decreasing direct ownership by 11% to 25,757 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 517d
  President and CEO Watts Ryan J. was granted 54,180 shares, increasing direct ownership by 23% to 289,987 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 517d
  COFO and Secretary Schuth Alexander O. was granted 54,180 shares, increasing direct ownership by 26% to 259,470 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 517d
  Chief Medical Officer Ho Carole was granted 54,180 shares, increasing direct ownership by 40% to 190,835 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 522d
  Director Krognes Steve E. sold $607,500 worth of shares (30,000 units at $20.25), decreasing direct ownership by 51% to 29,096 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 522d
  Director Sato Vicki L sold $64,403 worth of shares (3,080 units at $20.91), decreasing direct ownership by 3% to 107,976 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 525d
  COFO and Secretary Schuth Alexander O. exercised 6,708 shares at a strike of $5.28, increasing direct ownership by 3% to 205,290 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 559d
  Chief Medical Officer Ho Carole exercised 17,845 shares at a strike of $0.68, increasing direct ownership by 15% to 136,655 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 559d
  COFO and Secretary Schuth Alexander O. exercised 20,516 shares at a strike of $0.68 (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 573d
  Director Schenkein David P exercised 47,165 shares at a strike of $18.00 and sold $1,932,665 worth of shares (59,441 units at $32.51), decreasing direct ownership by 57% to 9,220 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 574d
  COFO and Secretary Schuth Alexander O. exercised 15,558 shares at a strike of $5.28 and sold $465,286 worth of shares (15,558 units at $29.91) (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 574d
  Director Sato Vicki L sold $30,600 worth of shares (1,020 units at $30.00), decreasing direct ownership by 0.91% to 111,056 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 581d
  Director Sato Vicki L sold $83,376 worth of shares (3,080 units at $27.07), decreasing direct ownership by 3% to 112,076 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 595d
  President and CEO Watts Ryan J. exercised 40,000 shares at a strike of $0.68 and sold $1,107,600 worth of shares (40,000 units at $27.69) (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 615d
  Director Krognes Steve E. sold $870,900 worth of shares (30,000 units at $29.03), decreasing direct ownership by 51% to 29,096 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 631d
  Director Sato Vicki L sold $30,600 worth of shares (1,020 units at $30.00), decreasing direct ownership by 0.88% to 115,156 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 642d
  Director Sato Vicki L sold $77,007 worth of shares (3,080 units at $25.00), decreasing direct ownership by 3% to 116,176 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 656d
  President and CEO Watts Ryan J. sold $53,765 worth of shares (2,260 units at $23.79), decreasing direct ownership by 0.95% to 235,807 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 656d
  Director Krognes Steve E. sold $41,085 worth of shares (1,727 units at $23.79), decreasing direct ownership by 5% to 32,677 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 656d
  COFO and Secretary Schuth Alexander O. sold $200,401 worth of shares (8,353 units at $23.99), decreasing direct ownership by 4% to 178,066 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 656d
  Chief Medical Officer Ho Carole sold $549,928 worth of shares (22,458 units at $24.49), decreasing direct ownership by 16% to 118,810 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 663d
  COFO and Secretary Schuth Alexander O. sold $52,006 worth of shares (2,272 units at $22.89), decreasing direct ownership by 1% to 186,419 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 663d
  Chief Medical Officer Ho Carole sold $53,494 worth of shares (2,337 units at $22.89), decreasing direct ownership by 2% to 141,268 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 705d
  Director Krognes Steve E. sold $678,660 worth of shares (30,688 units at $22.11), decreasing direct ownership by 35% to 34,404 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 705d
  Director Sato Vicki L sold $68,204 worth of shares (3,080 units at $22.14), decreasing direct ownership by 3% to 119,256 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 728d
  Director Cook Jennifer E. sold $31,682 worth of shares (1,458 units at $21.73), decreasing direct ownership by 7% to 20,038 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 734d
  Krognes Steve E. was granted 5,967 shares, increasing direct ownership by 13% to 53,308 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 734d
  Thornberry Nancy was granted 5,967 shares, increasing direct ownership by 47% to 18,680 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 734d
  Tessier-Lavigne Marc was granted 5,967 shares, increasing direct ownership by 0.32% to 1,880,539 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)
• 734d
  Sato Vicki L was granted 5,967 shares, increasing direct ownership by 5% to 122,336 units (SEC Form 4)

  4 - Denali Therapeutics Inc. (0001714899) (Issuer)

Other DNLI categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends